#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant  $\boxtimes$ 

Filed by a Party other than the Registrant  $\Box$ 

Check the appropriate box:

- Preliminary Proxy Statement
- $\Box$  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- □ Soliciting Material Pursuant to §240.14a-12

## **Oncternal Therapeutics, Inc.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- $\boxtimes$  No fee required
- □ Fee paid previously with preliminary materials
- □ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



Oncternal Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on June 16, 2022 For Stockholders of record as of April 18, 2022

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares We encourage you to access and review all of the important

information contained in the proxy materials before voting. To view the proxy materials, and to obtain directions to attend the

meeting, go to: www.proxydocs.com/ONCT To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



#### For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/ONCT

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 06, 2022.

To order paper materials, use one of the following methods.



# Oncternal Therapeutics, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2

PROPOSAL

 To elect three directors for a three-year term to expire at the 2025 Annual Meeting of Stockholders 1.01 James B. Breitmeyer, M.D., Ph.D.
1.02 Michael G. Carter, M.B., Ch.B, F.R.C.P.
1.03 David F. Hale

- 2. Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2022
- 3. To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof